These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8605674)

  • 1. Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up.
    Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Dombernowsky P
    Clin Chem; 1996 Apr; 42(4):564-75. PubMed ID: 8605674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse.
    Vizcarra E; Lluch A; Cibrián R; Jarque F; García-Conde J
    Oncology; 1994; 51(6):491-6. PubMed ID: 7970492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of CA 15.3, CEA and TPA concentrations during monitoring of breast cancer.
    Sölétormos G; Petersen PH; Dombernowsky P
    Clin Chem Lab Med; 2000 May; 38(5):453-63. PubMed ID: 10952230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of serum tumor markers for the diagnosis and follow-up of breast cancer.
    Barrenetxea G; Schneider J; Llorente MF
    Oncology; 1998; 55(5):447-9. PubMed ID: 9732223
    [No Abstract]   [Full Text] [Related]  

  • 5. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer.
    Kristiansen S; Jørgensen LM; Hansen MH; Nielsen D; Sölétormos G
    Biomed Res Int; 2015; 2015():986024. PubMed ID: 26339655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum tumor marker kinetics and the clinical course of patients with advanced breast cancer.
    Sonoo H; Kurebayashi J
    Surg Today; 1996; 26(4):250-7. PubMed ID: 8727945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Description of a computer program to assess cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen information during monitoring of metastatic breast cancer.
    Sölétormos G; Schiøler V
    Clin Chem; 2000 Aug; 46(8 Pt 1):1106-13. PubMed ID: 10926890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA.
    Sölétormos G; Nielsen D; Schiøler V; Mouridsen H; Dombernowsky P
    Eur J Cancer; 2004 Mar; 40(4):481-6. PubMed ID: 14962712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations.
    Nicolini A; Carpi A; Ferrari P; Pieri L
    Tumour Biol; 2003; 24(6):275-80. PubMed ID: 15004486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study.
    Kurebayashi J; Nishimura R; Tanaka K; Kohno N; Kurosumi M; Moriya T; Ogawa Y; Taguchi T
    Breast Cancer; 2004; 11(4):389-95. PubMed ID: 15604995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease.
    Bottini A; Berruti A; Tampellini M; Morrica B; Brunelli A; Gnocchi E; Brizzi MP; Aguggini S; Fara E; Alquati P; Dogliotti L
    Tumour Biol; 1997; 18(5):301-10. PubMed ID: 9276030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of tissue polypeptide antigen (TPA) with cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in follow-up of breast cancer.
    Findeisen R; Albrecht S; Richter B; Deutschmann K; Distler W
    Clin Chem Lab Med; 1998 Nov; 36(11):841-6. PubMed ID: 9877089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer.
    Yonemori K; Katsumata N; Noda A; Uno H; Yunokawa M; Nakano E; Kouno T; Shimizu C; Ando M; Tamura K; Takeuchi M; Fujiwara Y
    J Cancer Res Clin Oncol; 2008 Nov; 134(11):1199-206. PubMed ID: 18528707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of preoperative CA 15-3 levels in operable breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
    Iaffaioli RV; Caponigro F; Esposito G; Pagliarulo C; Deplacido S; Ungaro B; Bazzicalupo L; Frasci G; Bianco AR
    Int J Biol Markers; 1991; 6(1):21-4. PubMed ID: 1856513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
    Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
    World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on "spiking" phenomena.
    Yasasever V; Dinçer M; Camlica H; Karaloğlu D; Dalay N
    Clin Biochem; 1997 Feb; 30(1):53-6. PubMed ID: 9056110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of serum carcinoembryonic antigen and CA 15-3 in monitoring advanced breast cancer patients treated with systemic therapy: a large-scale retrospective study.
    Kurebayashi J; Yamamoto Y; Tanaka K; Kohno N; Kurosumi M; Moriya T; Nishimura R; Ogawa Y; Taguchi T;
    Breast Cancer; 2003; 10(1):38-44. PubMed ID: 12525762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.